Small cell lung cancer (SCLC) is the most lethal subtype of lung cancer and while it is characterized by sensitivity to initial chemotherapy, almost all SCLC patients experience relapse, and most die within a year of the initial diagnosis. We propose to profile the transcriptome and epigenome of SCLC using a genetically engineered mouse model system as well as human SCLC samples to identify the molecular alterations associated with SCLC recurrence. If successful, the project will result in the generation of an invaluable new pre-clinical model of SCLC and pilot data for an R01 grant application.

NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.